These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30989645)

  • 21. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
    Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
    Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
    Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC.
    Siekmeier R; Lattke P; Mix C; Park JW; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):137-45. PubMed ID: 11509920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir.
    Guo Z; Caro L; Robertson MN; Hwang P; Hoover P; Wudarski C; Maiuri K; Wang YH; Mogg R; Mehrotra DV; Blanchard R; Shaw PM
    Pharmacogenomics; 2019 Jun; 20(9):631-641. PubMed ID: 31250727
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
    Deng JW; Song IS; Shin HJ; Yeo CW; Cho DY; Shon JH; Shin JG
    Pharmacogenet Genomics; 2008 May; 18(5):424-33. PubMed ID: 18408565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers.
    Xiang Y; Okochi H; Kozachenko I; Sodhi JK; Frassetto LA; Benet LZ
    Clin Pharmacol Ther; 2021 Aug; 110(2):480-485. PubMed ID: 33880760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin.
    Rajput TA; Naveed AK; Farooqi ZR; Khan S
    Pak J Pharm Sci; 2017 Jul; 30(4):1363-1370. PubMed ID: 29039339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
    Smit JW; Wijnne HJ; Schobben F; Sitsen A; de Bruin TW; Erkelens DW
    Am J Cardiol; 1995 Jul; 76(2):89A-96A. PubMed ID: 7604808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
    Misaka S; Abe O; Sato H; Ono T; Shikama Y; Onoue S; Yabe H; Kimura J
    Eur J Clin Pharmacol; 2018 May; 74(5):601-609. PubMed ID: 29368187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations.
    Xiang Q; Wu W; Zhao N; Li C; Xu J; Ma L; Zhang X; Xie Q; Zhang Z; Wang J; Xu W; Zhao X; Cui Y
    Asian J Pharm Sci; 2020 Mar; 15(2):264-272. PubMed ID: 32373204
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Ragia G; Atzemian N; Maslarinou A; Manolopoulos VG
    Drug Metab Pers Ther; 2022 Dec; 37(4):347-352. PubMed ID: 36169244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.
    Hirvensalo P; Tornio A; Neuvonen M; Tapaninen T; Paile-Hyvärinen M; Kärjä V; Männistö VT; Pihlajamäki J; Backman JT; Niemi M
    Clin Pharmacol Ther; 2018 Jul; 104(1):158-168. PubMed ID: 28940478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
    Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.
    Meadowcroft AM; Williamson KM; Patterson JH; Hinderliter AL; Pieper JA
    J Clin Pharmacol; 1999 Apr; 39(4):418-24. PubMed ID: 10197301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the
    Kim CO; Oh ES; Kim H; Park MS
    Drug Des Devel Ther; 2017; 11():503-512. PubMed ID: 28260863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
    Ochoa D; Prieto-Pérez R; Román M; Talegón M; Rivas A; Galicia I; Abad-Santos F; Cabaleiro T
    Pharmacogenomics; 2015; 16(9):939-48. PubMed ID: 26122864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacogenomics in routine medical care].
    Rosskopf D; Meyer zu Schwabedissen HE; Kroemer HK; Siegmund W
    Dtsch Med Wochenschr; 2010 Jan; 135(4):133-44; quiz 145-6. PubMed ID: 20101557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation.
    Bi YA; Lin J; Mathialagan S; Tylaska L; Callegari E; Rodrigues AD; Varma MVS
    Mol Pharm; 2018 Mar; 15(3):1284-1295. PubMed ID: 29433307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.
    Wu JC; Nafziger AN; Bertino JS; Ma JD
    Drug Metab Lett; 2012 Jun; 6(2):94-101. PubMed ID: 22594566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.